ReviewBritish journal of clinical pharmacology2014
Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.
Review in British journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Drug delivery strategies for the treatment of relapse behavior in substance use disorder- A systematic review.Metabolic brain disease · 2025Pooled it
- Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction (Abingdon, England) · 2018Pooled it
- Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.Addiction science & clinical practice · 2022Trial
- Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.The lancet. HIV · 2019Trial
- Evaluating the antagonist effect of naltrexone implant via opioid challenge tests with escalating doses of hydromorphone injection in former heroin dependent patients.Frontiers in psychiatry · 2025Article
- Nanotherapeutics for Alleviating Anesthesia-Associated Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- The Utilization of Low Dose Naltrexone for Chronic Pain.CNS drugs · 2023Article
- Naltrexone Implant for Opioid Use Disorder.Neurology international · 2021Review
- Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study).Contemporary clinical trials communications · 2021Article
- Management of Sedation and Analgesia in Critically Ill Patients Receiving Long-Acting Naltrexone Therapy for Opioid Use Disorder.Annals of the American Thoracic Society · 2020Article
- Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual.Journal of systems and integrative neuroscience · 2020Article
- Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation.Health & justice · 2020Article
- Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.The American journal of psychiatry · 2018Article
- Advances in the delivery of buprenorphine for opioid dependence.Drug design, development and therapy · 2017Review
- Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption.BioMed research international · 2017Review
- Opioid Use in the Twenty First Century: Similarities and Differences Across National Borders.Current treatment options in psychiatry · 2016Article
- Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist.Postgraduate medical journal · 2016Review
- Themed section.British journal of pharmacology · 2015Article
- Drugs for addiction: a therapeutic area in need of a 'shot in the arm'.British journal of clinical pharmacology · 2014Article
- A comprehensive approach to addiction medicine as an appropriate response to the HIV epidemic among drug users.Journal of food and drug analysis · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sustained release technologies for administering the opioid antagonist naltrexone (SRX) have the potential to assist opioid-addicted patients in their efforts to maintain abstinence from heroin and other opioid agonists. Recently, reliable SRX formulations in intramuscular or implantable polymers that release naltrexone for 1-7 months have become available for clinical use and research. This qualitative review of the literature provides an overview of the technologies currently available for SRX and their effectiveness in reducing opioid use and other relevant outcomes. The majority of studies indicate that SRX is effective in reducing heroin use, and the most frequently studied SRX formulations have acceptable adverse events profiles. Registry data indicate a protective effect of SRX on mortality and morbidity. In some studies, SRX also seems to affect other outcomes, such as concomitant substance use, vocational training attendance, needle use, and risk behaviour for blood-borne diseases such as hepatitis or human immunodeficiency virus. There is a general need for more controlled studies, in particular to compare SRX with agonist maintenance treatment, to study combinations of SRX with behavioural interventions, and to study at-risk groups such as prison inmates or opioid-addicted pregnant patients. The literature suggests that sustained release naltrexone is a feasible, safe and effective option for assisting abstinence efforts in opioid addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.